BioCentury | Jun 2, 2020
Finance

Hillhouse-backed $160M series B round to drive Genor’s first candidate to the market

Genor plans to establish a commercial team and take its first checkpoint inhibitor to market for a new indication after raising a $160 million series B round led by existing investor Hillhouse Capital. New investors...
BioCentury | May 23, 2020
Product Development

Hot topics at ASCO 2020

Center stage at this year’s virtual ASCO meeting are a series of hot topics that demonstrate the transformative potential of a single data readout or regulatory update. Areas to watch include next-generation checkpoint targets, where...
BioCentury | May 6, 2020
Product Development

May 5 Quick Takes: Data propel Adverum, TG, Akebia stocks; plus Tolmar, SRI-Exscientia, Sino-GeoVax

TG’s combo meets Phase III leukemia endpoint  TG Therapeutics Inc. (NASDAQ:TGTX) climbed $4.23 (34%) to $16.69 on Tuesday after CD20 inhibitor ublituximab plus PI3Kδ inhibitor umbralisib met the primary endpoint of progression-free survival (PFS) in...
BioCentury | Apr 30, 2020
Deals

Adicet to become public company via resTORbio merger

Cell therapy developer Adicet will merge with resTORbio to form a public company that will trade under Adicet’s name. The combined company will develop Adicet Bio Inc.’s pipeline of allogeneic γδ T cell therapies, including...
BioCentury | Apr 8, 2020
Deals

Zai adds second bispecific to pipeline via Regeneron deal

In Zai’s latest deal giving it local rights to a therapeutic developed in the West, the Shanghai-based biotech has partnered with Regeneron for REGN1979, a bispecific antibody that is in Phase II testing to treat...
BioCentury | Feb 27, 2020
Product Development

Amgen banks on speed to maintain edge in two hot cancer spaces

Amgen has a first-mover advantage in two of the hottest areas of cancer R&D -- K-Ras and bispecific antibodies. To stay ahead, it’s banking on a combination of rapid clinical development and moving to earlier...
BioCentury | Feb 25, 2020
Finance

Feb. 24 Financial Quick Takes: Bio-Thera shines in first days on STAR; plus ImmuneOnco, GenCells, Twist and Axovant

Fast start for Bio-Thera on Shanghai’s STAR board  Bio-Thera Solutions Ltd. (Shanghai:688177) jumped RMB27.44 (84%) to RMB60.20 in its first day of trading Friday before edging up to RMB60.90 Monday on Shanghai’s STAR board. The...
BioCentury | Jan 11, 2020
Finance

Why buysiders say 2020 could be the year of the CNS

A pair of CNS approvals in the final days of 2019 has only added to the growing momentum buysiders were already tracking for 2020 in the once neglected disease area. Positive regulatory signals are converging...
BC Innovations | Dec 6, 2019
Targets & Mechanisms

Bispecifics and allogeneics steal the spotlight from autologous CAR Ts

Standing out at this year's ASH meeting is a pair of growing threats to first-generation CAR T cell therapies: bispecific antibodies and allogeneic cell therapies. Gone are the days when autologous CAR Ts were the...
BioCentury | Oct 25, 2019
Product Development

Deciding factors in the shifting MS treatment landscape

The efficacy and convenience advantages that established oral medicines as the go-to therapy in multiple sclerosis are the same factors now squeezing them out. Two years post-launch, the success of injectable Ocrevus ocrelizumab from Roche...
Items per page:
1 - 10 of 1276